Interleukin 2 (IL-2) is the only systemic treatment currently available that is capable of curing patients with metastatic renal cell cancer (RCC). The first indications that IL-2 could mediate ...

Interleukin-2 (IL-2) is a pluripotent cytokine that regulates the immune system’s response. The IL-2 receptor (IL-2R) is a heterotrimeric protein that binds to IL-2 and reacts to it on the ...

The study met its primary and secondary endpoints, demonstrating that treatment with low-dose interleukin-2 is safe and well-tolerated in patients with Alzheimer’s. Also Read: EXCLUSIVE ...

Interleukin 2, or IL-2, is a pleiotropic cytokine that plays a vital role in the regulation of T-cell responses. IL-2 also plays a crucial role in an extensive range of other immune modulatory ...

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101.

US-based immuno-oncology company Aulos Bioscience has announced the first patients have been dosed as part of a trial ...

Discover a trial in which patients received either IL-2 or a placebo for 5 days, followed by weekly doses for 4 weeks.

Medicenna Therapeutics (MDNA) presented updated clinical results from the ongoing monotherapy dose expansion and combination dose escalation portions of the Phase 1/2 ABILITY-1 study evaluating MDNA11 ...

A live webcast link for the Evercore ISI HealthCONx Conference fireside chat will be available at https://investors.werewolftx.com/news-and-events/events. An archived replay will be available for ...